文献速递神经肿瘤

双靶点IGF1R/IR抑制剂联合GD2-CAR T细胞在H3K27M突变型弥漫性中线胶质瘤中显示强效抗肿瘤活性

Dual IGF1R/IR inhibitors in combination with GD2-CAR T-cells display a potent anti-tumor activity in diffuse midline glioma H3K27M-mutant.
PubMed 文献 · Neuro Oncol · 2022-01-01

本研究检测弥漫性中线胶质瘤(DMG)及儿童高级别胶质瘤中GD2的表达,并用高通量细胞筛选法从42种激酶抑制剂中寻找可增强GD2-CAR T细胞疗效的化合物。结果显示GD2在受检组织中以异质性但广泛的方式表达,双靶点IGF1R/IR抑制剂BMS-754807与linsitinib可在不影响CAR T细胞的浓度下抑制肿瘤细胞活力,其中linsitinib还能降低GD2-CAR T细胞的活化/耗竭并增强其中央记忆表型,联合方案在DIPG模型体外、离体及体内均显示增强的抗肿瘤活性。

要点

  • GD2在受检DMG/DIPG组织中呈异质性但广泛表达,在H3K27M突变型细胞系中表达均一。
  • BMS-754807与linsitinib可在不影响CAR T细胞的浓度下抑制DIPG肿瘤细胞活力。
  • linsitinib联合GD2-CAR T细胞的抗肿瘤活性在DIPG体外、离体及体内模型中得到证实。

核心结论

  • 作者认为本研究支持开发IGF1R/IR抑制剂与GD2-CAR T细胞联合用于治疗DMG/DIPG患者,并可能用于儿童高级别胶质瘤(pHGG)。

研究设计与样本

  • 基础研究:对肿瘤组织样本行免疫组化、对原代患者来源细胞系行免疫荧光以研究GD2表达。
  • 建立高通量细胞筛选法,从42种激酶抑制剂中筛选与GD2-CAR T细胞联合的候选化合物。
  • 采用细胞活力检测、蛋白质印迹、流式细胞术、实时PCR、DIPG三维培养模型及原位异种移植模型评估候选化合物对DIPG细胞死亡及CAR T细胞功能的影响。

主要发现

  • GD2在受检组织中呈异质性但广泛表达,而在DMG/DIPG H3K27M突变型细胞系中表达均一。
  • 鉴定出双靶点IGF1R/IR拮抗剂BMS-754807与linsitinib,可在不影响CAR T细胞的浓度下抑制肿瘤细胞活力。
  • linsitinib(而非BMS-754807)降低GD2-CAR T细胞的活化/耗竭并增加其中央记忆表型。
  • linsitinib联合GD2-CAR T细胞的增强抗肿瘤活性在DIPG模型的体外、离体及体内实验中得到证实。

临床怎么用

  • 作者认为本研究支持开发IGF1R/IR抑制剂与GD2-CAR T细胞联合用于治疗DMG/DIPG患者,并可能用于pHGG。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Diffuse midline gliomas (DMG) H3K27M-mutant, including diffuse intrinsic pontine glioma (DIPG), are pediatric brain tumors associated with grim prognosis. Although GD2-CAR T-cells demonstrated significant anti-tumor activity against DMG H3K27M-mutant in vivo, a multimodal approach may be needed to more effectively treat patients. We investigated GD2 expression in DMG/DIPG and other pediatric high-grade gliomas (pHGG) and sought to identify chemical compounds that would enhance GD2-CAR T-cell anti-tumor efficacy. METHODS: Immunohistochemistry in tumor tissue samples and immunofluorescence in primary patient-derived cell lines were performed to study GD2 expression. We developed a high-throughput cell-based assay to screen 42 kinase inhibitors in combination with GD2-CAR T-cells. Cell viability, western blots, flow-cytometry, real time PCR experiments, DIPG 3D culture models, and orthotopic xenograft model were applied to investigate the effect of selected compounds on DIPG cell death and CAR T-cell function. RESULTS: GD2 was heterogeneously, but widely, expressed in the tissue tested, while its expression was homogeneous and restricted to DMG/DIPG H3K27M-mutant cell lines. We identified dual IGF1R/IR antagonists, BMS-754807 and linsitinib, able to inhibit tumor cell viability at concentrations that do not affect CAR T-cells. Linsitinib, but not BMS-754807, decreases activation/exhaustion of GD2-CAR T-cells and increases their central memory profile. The enhanced anti-tumor activity of linsitinib/GD2-CAR T-cell combination was confirmed in DIPG models in vitro, ex vivo, and in vivo. CONCLUSION: Our study supports the development of IGF1R/IR inhibitors to be used in combination with GD2-CAR T-cells for treating patients affected by DMG/DIPG and, potentially, by pHGG.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. de Billy E, Pellegrino M, Orlando D, et al. Dual IGF1R/IR inhibitors in combination with GD2-CAR T-cells display a potent anti-tumor activity in diffuse midline glioma H3K27M-mutant. Neuro Oncol. 2022. PMID: 34964902. doi:10.1093/neuonc/noab300

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。